Acousticon receives FDA clearance for ACAM-5 hearing loss product

May 9 2011

TCG (Technology Commercialization Group LLC) today announced that Acousticon Inc., one of its portfolio companies, recently received FDA clearance for its ACAM-5 product, allowing the company to begin US commercialization activities for the first time. The ACAM-5 is a German engineered product that helps hearing professionals understand the scope and depth of a patient's hearing loss in order to optimize the performance of hearing aids. Robert Keefer, PhD, is President of Acousticon, Inc. and also a Partner at TCG, an international business development, strategy and implementation firm, that has launched five European medical companies in the US in the last five years.

• "European Medtech companies continue to have an excellent opportunity to increase their sales by expanding into the US market, " said Dr. Keefer.
• "The opportunities to enter the US for the first time couldn't come at a better time for many EU companies, many of whom want to grow sales beyond their home markets, "said Dr. Reinhard Merz, a TCG partner who works out of the firm's European office.
• Dr. Merz added, "Importantly, many companies aren't aware of the variety of options available to them for entering the US or improving existing operations in the largest Medtech market in the world. The successful partnership between Acousticon and TCG is another example of how European companies are finding creative ways to improve their chances of success in the US, while at the same time de-risking the overall investment".